Literature DB >> 16458083

Characterization of the expression of the ALK receptor tyrosine kinase in mice.

Emma Vernersson1, Nelson K S Khoo, Maria L Henriksson, Göran Roos, Ruth H Palmer, Bengt Hallberg.   

Abstract

Anaplastic Lymphoma Kinase (ALK), a receptor tyrosine kinase, was first described as the fusion product causing a subtype of non-Hodgkin's lymphoma. To date Alk has been reported to be mainly expressed in CNS and other parts of the brain. Here we describe an extensive characterization of the mRNA and protein expression of ALK during mouse development. We show that mRNA and ALK protein show overlapping expressing patterns in specific regions of the central and the peripheral nervous systems. Furthermore, ALK is also expressed in the eye, nasal epithelium, olfactory nerve, tongue, skin, tissue surrounding the esophagus, stomach and midgut but not the hindgut. Expression of ALK is also found in testis and ovary.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16458083     DOI: 10.1016/j.modgep.2005.11.006

Source DB:  PubMed          Journal:  Gene Expr Patterns        ISSN: 1567-133X            Impact factor:   1.224


  61 in total

Review 1.  Emerging importance of ALK in neuroblastoma.

Authors:  Anna M Azarova; Gargi Gautam; Rani E George
Journal:  Semin Cancer Biol       Date:  2011-09-16       Impact factor: 15.707

2.  Anterograde Jelly belly ligand to Alk receptor signaling at developing synapses is regulated by Mind the gap.

Authors:  Jeffrey Rohrbough; Kendal Broadie
Journal:  Development       Date:  2010-10       Impact factor: 6.868

Review 3.  Targeting oncogenic ALK and MET: a promising therapeutic strategy for glioblastoma.

Authors:  Gerald C Wallace; Yaenette N Dixon-Mah; W Alex Vandergrift; Swapan K Ray; Catherine P Haar; Amber M Mittendorf; Sunil J Patel; Naren L Banik; Pierre Giglio; Arabinda Das
Journal:  Metab Brain Dis       Date:  2013-04-02       Impact factor: 3.584

4.  Anaplastic lymphoma kinase regulates binge-like drinking and dopamine receptor sensitivity in the ventral tegmental area.

Authors:  John W Dutton; Hu Chen; Chang You; Mark S Brodie; Amy W Lasek
Journal:  Addict Biol       Date:  2016-01-11       Impact factor: 4.280

Review 5.  Treating ALK-positive lung cancer--early successes and future challenges.

Authors:  D Ross Camidge; Robert C Doebele
Journal:  Nat Rev Clin Oncol       Date:  2012-04-03       Impact factor: 66.675

6.  Role of the p55-gamma subunit of PI3K in ALK-induced cell migration: RNAi-based selection of cell migration regulators.

Authors:  Minchul Seo; Jong-Heon Kim; Kyoungho Suk
Journal:  Cell Adh Migr       Date:  2016-06-20       Impact factor: 3.405

Review 7.  The duality of human oncoproteins: drivers of cancer and congenital disorders.

Authors:  Pau Castel; Katherine A Rauen; Frank McCormick
Journal:  Nat Rev Cancer       Date:  2020-04-27       Impact factor: 60.716

8.  Pharmacological inhibition of Receptor Protein Tyrosine Phosphatase β/ζ (PTPRZ1) modulates behavioral responses to ethanol.

Authors:  Rosalía Fernández-Calle; Marta Vicente-Rodríguez; Miryam Pastor; Esther Gramage; Bruno Di Geronimo; José María Zapico; Claire Coderch; Carmen Pérez-García; Amy W Lasek; Beatriz de Pascual-Teresa; Ana Ramos; Gonzalo Herradón
Journal:  Neuropharmacology       Date:  2018-05-09       Impact factor: 5.250

Review 9.  Anaplastic lymphoma kinase: role in cancer pathogenesis and small-molecule inhibitor development for therapy.

Authors:  Thomas R Webb; Jake Slavish; Rani E George; A Thomas Look; Liquan Xue; Qin Jiang; Xiaoli Cui; Walter B Rentrop; Stephan W Morris
Journal:  Expert Rev Anticancer Ther       Date:  2009-03       Impact factor: 4.512

Review 10.  Anaplastic lymphoma kinase: signalling in development and disease.

Authors:  Ruth H Palmer; Emma Vernersson; Caroline Grabbe; Bengt Hallberg
Journal:  Biochem J       Date:  2009-05-27       Impact factor: 3.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.